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Thereisevidenceinsepsis,bothinrodentsandinhumans,thatactivationofthecomplementsystemresultsinexcessiveproduction
of C5a, which triggers a series of events leading to septic shock, multiorgan failure, and lethality. In rodents following cecal ligation
and puncture (CLP), which induces polymicrobial sepsis, in vivo blockade of C5a using neutralizing antibodies dramatically
improved survival, reduced apoptosis of lymphoid cells, and attenuated the ensuing coagulopathy. Based on these data, it seems
reasonabletoconsidertherapeuticblockadeofC5ainhumansenteringintosepsisandsepticshock.Strategiesforthedevelopment
of such an antibody for use in humans are presented.
1.Introduction
Sepsis and septic shock are very challenging medical prob-
lems for which speciﬁc interventional therapy is currently
extremely limited. The resulting outcome is substantial
lethality. In both experimental (polymicrobial) sepsis and
human sepsis/septic shock there is evidence for robust
activation of the complement system, resulting in release of
extremely strong proinﬂammatory products such as C5a, an
anaphylatoxin that reacts with its receptors (C5aR, C5L2)
on phagocytes (neutrophils, macrophages) and on a variety




2 and H2O2, and other responses) [1]. The complement
system is a key component of the innate immune system,
activation of which results in production of C3b (from C3),
which is a key opsonic factor reactive with receptors on
phagocytes to promote internalization of bacteria and their
subsequent destruction. An activation product of the distal
complement pathway that reﬂects the innate immune system
is the membrane attack complex (C5b-9) which causes lysis
of Gram-negative bacteria. C3a and C5a anaphylatoxins are
small cleavage products from C3 and C5 and possess proin-
ﬂammatory activities, especially C5a. As sepsis development
proceeds, there is a burst of C5a production which results
in excessive activation of phagocytic cells, often leading to
paralysis of MAPK signaling pathways [2]. Also part of the
response to sepsis is upregulation of C5aR on a variety of
nonphagocytic cells in liver, spleen, kidneys, and lungs
[3], which, when interactive with C5a, is associated with
multiorgan failure. In this paper, we will review evidence,
mostly from our own laboratories, regarding the ability of
neutralizing antibody to C5a to dramatically reduce lethali-
tyinseptic rodentsaswellasreducingapoptosis oflymphoid
cells (leading to immunodeﬁciency) and the coagulopathy of
sepsis. We will also discuss issues regarding the development
of antibodies to human C5a that might mitigate the compli-
cations of sepsis.
2. Complement Pathway Activation
Figure 1 is a simpliﬁed version of the various pathways of
complement activation.
The traditional pathways include the classical pathway
(which sequentially activates C1, C4, and C2 to produce
the C3 convertase) and the mannan binding lectin (MBL)
pathway (also known as mannan binding protein, MBP)
in which MBP binds to mannose-rich glycans on bacterial
surfaces. This leads to activation, depending on the species,
of mannan-binding lectin-associated serine proteases [1–3]
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Figure 1: Simpliﬁed view of intrinsic and extrinsic pathways of complement activation. Boxes show major activation products of com-
plement activation and the biological consequences of these products.
C1s of the classical pathway. The end result is cleavage of
C4 and C2 to form C4b2a, the C3 convertase that will then
generate C3a and C3b. The third pathway of complement
activation is related to the constant, spontaneous hydrolysis
of C3, resulting in formation of C3b, which then triggers
complementactivation.Anextrinsicpathwayofcomplement
activation relates to direct activation (cleavage) of C5 by
cell/tissue/plasma neutral proteases (such as thrombin and
proteases released from neutrophils and macrophages),
resulting in formation of C5a and C5b. Figure 1 also shows
(in boxes) the complement activation products that are
relevant in sepsis. These are C5a and C3b, the latter being
a major opsonic factor reactive with bacteria to promote
their phagocytosis. It is clear that C3b is a major product
facilitating the protective eﬀects of complement in the
innate immune system, providing a protective shield against
infections agents. Targeting C3 or its activation products
especially C3b in the setting of sepsis, unless very carefully
regulated, has the potential to depress the opsonic system,
whichisvitalfortheinvivoresponsetobacteriainthesetting
of sepsis. C5a is a very powerful phlogistic product of the
complement system which, in the setting of sepsis and when
produced in excessive quantities, can result in catastrophic
outcomes, which will be discussed below. The ability to
dampen the eﬀects of C5a includes its in vivo neutralization
or blockade in vivo of its two receptors, C5aR and C5L2.
Finally,productionofthemembraneattackcomplex(C5b-9)
may play a protective role in the setting of sepsis, since C5b-9
has the ability to engage in lysis of Gram-negative bacteria.
For this reason, the use of antibodies to deplete C5 in vivo
willdepressC5ageneration,reducingtheproductionofC5b-
9, which is an undesirable outcome (described below).
3.SurvivalafterCLPBasedon
Mouse Genotypes
We have employed CLP in C57BL/6 young adult males
(25gm) and have used various genotypes, as described in
Table 1.
Two grades of CLP, as recently described in detail [4]
have been employed. High-grade sepsis (75% of cecum
ligated) in Wt mice resulted in no survivals by the end of
day 3 [4]. Use of similar septic conditions in C5aR−/− or
C5L2−/− mice resulted in survival rates on day 3 of 85%
and 80%, respectively, suggesting that engagement of both
C5a receptors, perhaps operating in sequence, results in
highlyadverseoutcomes,asseeninWtmice.Datasuggesting
sequentialengagementofthetwoC5areceptorsinthesetting
of sepsis indicated that the bulk of the proinﬂammatory
mediators appearing in plasma 24hr after CLP were reduced
by ≥80% in the k. o. mice [5]. The fact that absence of either
receptor resulted in suppression of mediator production far
above the 50% level suggests that there may be some typeCritical Care Research and Practice 3
Table 1: Survival of k. o. mice after CLP.
Grade of CLP Genotype Time after CLP Survival
High grade∗ Wt Day 3 0%
High grade C5aR−/− Day 3 85%
High grade C5L2−/− Day 3 80%
Intermediate grade∗∗ Wt Day 7 31%
Intermediate grade C3−/− Day 7 5%
Intermediate grade C5−/− Day 7 15%
Intermediate grade C5aR−/− Day 7 80%
Intermediate grade C5L2−/− Day 7 100%
∗,∗∗Grades as deﬁned in [2, 4].
of collaborative interaction between C5aR and C5L2 during
development ofsepsis. When intermediate grade sepsis (50%
of cecum ligated) was employed, survival rates in Wt, C3−/−
or C5−/− mice by day 7 were 31%, 5% and 15%, respectively.
In the case of C5aR−/− or C5L2−/− mice, survival rates
were 80% and 100%, respectively, correlating with results
in mice with high grade sepsis (top of Table 1). The high
lethality (95%) in C3−/− mice may be due to the inability to
generate the opsonic factor, C3b. The fact that C5−/− mice
did worse than the Wt mice even though no C5a formation
occurs could be related to inability to generate MAC (C5b-9)
which has lytic activity for Gram-negative bacteria (see
Section 7.3). Since we previously found that C3−/− mice, at
least in the setting of acute lung injury, can generate C5a via
the role of thrombin functioning as a C5 convertase [6], this
suggests that C3−/− mice can still generate some C5a, which
complicates interpretation of data. The parallel data of high
survival in C5aR−/− or C5L2−/− mice in both high grade
and intermediate grade sepsis is consistent with the idea that
both receptors act, perhaps simultaneously or sequentially,
to cause adverse consequences after onset of CLP.
4.Use ofBlockingAntibodiestoC5ain
AnimalSepsis
Experimental studies in the 1980s involving monkeys and
employing a rabbit anti-human polyclonal antibody to C5a
indicated that blockade of C5a by such antibodies could
signiﬁcantly attenuate live Escherichia coli-induced septic
shockandaccompanyingacuterespiratorydistresssyndrome
(ARDS) [7] and that such antibodies could signiﬁcantly
lower the C5a levels in monkey blood [8]. In a model
of severe sepsis in pigs due to infusion of live E. coli,
administration of a neutralizing monoclonal anti-pig C5a
antibody (not cross reactive with C5) led to signiﬁcantly
d e c r e a s e dl e v e l s( 7 5 % )o fI L - 6[ 9]. In the same model, this
antibody also was demonstrated to signiﬁcantly improve
the oxygen utilization during severe sepsis [10]. In studies
in rats it was suggested that LPS-induced septic shock was
associated with increased C5a levels in blood and that
equivalent septic shock features could be mimicked by
infusion of C5a. Blockade of C5a in this model with F(ab )2
fragmentsofrabbitanti-ratC5asigniﬁcantlyattenuatedLPS-
induced responses [11].
In recent work, the Michigan group has demonstrated
in rats following cecal ligation and puncture-induced sep-
sis that blockade of C5a with polyclonal rabbit anti-rat anti-
bodies signiﬁcantly improved survival in septic rats and low-
ered the intensity of the inﬂammatory responses (plasma/
serum/cytokines/chemokines) [12]. Diﬀerent anti-C5a pep-
tide antibodies (aﬃnity puriﬁed) to rat C5a were then in-
vestigated in the same model. Antibodies were directed to
diﬀerent regions of the C5a molecule, assuming that block-
a d eo fc e r t a i nr e g i o n so fC 5 aw o u l db ee x p e c t e dt op r o v i d e
the highest protective eﬀects after CLP [13]. Certain of these
antibodies were demonstrated to signiﬁcantly reduce the oc-
currence of multiorgan failure [14]. Details of these studies
are discussed below. The Michigan group also demonstrated
that polyclonal blocking antibodies directed against rat C5a
and cross-reacting with mouse C5a signiﬁcantly improved
survival in CLP-mice and that such improvement in survival
was comparable to the improvement that could be achieved
by employing a speciﬁc polyclonal anti-mouse C5a antibody
to C5aR in the same model [3]. In a recent study such results
were conﬁrmed by employing rabbit polyclonal anti-mouse
C5a antibody [5].
In addition to the data described above, numerous pub-
lications describe the use of polyclonal and monoclonal anti-
C5a antibodies and their eﬃcacies in models of inﬂamma-
tion such as ischemia/reperfusion injury, renal disease, graft
rejection,malaria,rheumatoidarthritis,infectiousboweldis-
ease, inﬂammatory lung disease, and lupus-like autoimmune
diseases. using various animal species (reviewed, [15]).
Table 2 demonstrates our studies dealing with the abil-
ities of antigen aﬃnity puriﬁed rabbit IgG preparations to
protectCLPrats(youngadult300gmmaleSprague-Dawley)
as a function of the antibody preparation and the time after
CLP of intravenous infusion of 600µgI g G[ 13].
When given just before CLP, antibody to the M region of
ratC5a(aminoacidresidues17–36)resultedin90%survival,
while antibody to the C region (residues 58–77) provided
equivalent survival (85%), which is contrast to preimmune
rabbitIgG,inwhichonly30%survivalensued.WhentheIgG
preparations were infused 6hr after onset of CLP, antibodies
to the M and C regions of rat C5a still provided good
protection, resulting in 70% and 60% survival, respectively,
while infusion of preimmune IgG at the same time after CLP
resulted in only 35% survival. When antibody infusions were
delayed until 12hr after CLP, antibodies to the M and C
regions still had impressive protective eﬀects, providing 50%
and 40% survival, respectively, while infusion of preimmune
IgG resulted in only 17% survival. Antibodies that were
generated and were reactive with the N terminal region
of rat C5a (residues 1–16) were ineﬀective in producing
beneﬁcial eﬀects in CLP rats (data not shown). Collectively,
these data indicate that neutralizing polyclonal antibodies to
two diﬀerent regions of rat C5a have signiﬁcantly protective
eﬀects by enhancing survival after CLP in rats. Furthermore,
the antibodies still had protective eﬀects when the infusion
was delayed for 6 or 12hr after CLP. This gives hope that,
in septic humans, infusion of C5a neutralizing antibodies
may be protective even if used in the later phases of sep-
sis.4 Critical Care Research and Practice
Table 2: Protective eﬀects of anti-C5a rabbit IgG in CLP rats.
Type of antibody Time for antibody infusion
(hr)∗∗
Survival at 7 days∗
Anti-C5aM Anti-C5aC Preimmune IgG
Rabbit IgG (600µg i.v.) 0 90% 85% 30%
Rabbit IgG (600µg i.v.) 6 70% 60% 35%
Rabbit IgG (600µg i.v.) 12 50% 40% 17%
∗Expressed as percent of all rats in each group (n ≥ 8). The M region of rat C5a involved amino acid residues 17–36 while the C region involved residues
58–77. Peptides were covalently linked to keyhole limpet hemocyanin followed by immunizations of rabbits. Antibodies were isolated by antigen aﬃnity
puriﬁcation. Adapted from data in [13].
∗∗Time (hr) of antibody infusion after CLP.
Table 3: Protective eﬀe c t so fm A bt or a tC 5 a ∗.
Treatment Amount
injected i.v. Survival (day 5)
Normal IgG2 1,000µg 10%
Anti-rat C5a mAb 1,000µg 70%
Anti-rat C5a mAb 400µg 65%
∗Monoclonal IgG2 obtained by immunization of C57Bl/6 mice with recom-
binantratC5a.Theantibodywas ofhighaﬃnitybased onplasmaresonance
measurements using a biosensor instrument.
5.Ability of Mouse Monoclonal Antibodies to
RatC5ato ImproveSurvivalafterCLP
Preliminary studies have been done using mouse mAbs to
rat C5a in order to determine if mAbs would also improve
survival in CLP rats. These antibodies (IgG2) were shown
by plasma resonance measurements to be of high aﬃnity,
although in these studies the epitopes on C5a that were
reactive with the mAb were not determined. As shown
in Table 3, using high grade CLP, 1000µgn o r m a lI g G 2
resulted in a 5 day survival of only 10%, whereas infusion of
1,000µg or 400µg of mAb resulted in 70% and 65% survival,
respectively.
6. Role of C5a in Apoptosis of Thymocytes
Apoptosis of T and B cells has been extensively described in
CLP mice [16, 17] and in septic humans [18]. These events
occur very early in the setting of sepsis in humans, often in
the ﬁrst 12hr after hospital admission and are thought to be
responsible for early development of immunosuppression in
humans and also in rodents. Treatment of mice with caspase
inhibitors before onset of sepsis enhanced survival [19]. We
have evaluated rats after onset of CLP and found over the
ﬁrst 48hr substantial loss of thymic mass (by 59%) (data
not shown). Treatment of these animals before CLP with
neutralizing antibody to rat C5a reduced the loss of thymic
mass to a value of 26% [20], allowing the interpretation that
C5a is in some manner linked to induction of thymocyte
apoptosis. In other studies we found a surprising result,
namely, that 3hr after CLP thymocytes showed a 65%
increased binding of 125I-C5a, associated with an early and
rapid increase in mRNA for C5aR [21]. In addition, in
Table 4: Activation of caspases in thymocytes after CLP.
Caspase Treatment∗
Normal IgG Anti-C5a IgG
3 3.72 1.75
6 3.0 1.63
8 No change No change
9 2.85 1.15
∗Expressed as fold increase in thymocytes 12hr after CLP. A fold change of
1.0 would represent no change in caspase activity. Caspase activity was ex-
pressed as release (pg/µg protein) of the ﬂuorogenic substrate 7-amino-4-
tri-ﬂuoromethyl coumarin (AFC) as described in [20].
vitro addition of C5a to thymocytes obtained from CLP rats
resulted in increased binding of Annexin V, which correlated
with caspase activation and apoptosis [21].
Caspase content was measured in rat thymocytes em-
ploying ﬂuorochrome peptide substrates speciﬁc for individ-
ual caspases, using thymocytes obtained from rats subjected
to CLP 12hr earlier. There were substantial elevations in
caspases 3 (nearly 4-fold), 6 (3-fold), and 9 (almost 3-fold)
in rats given 400µg preimmune rabbit IgG, while caspase 8
showed no elevation (Table 4).
In a companion set of CLP rats given 400µg neutralizing
antibody to C5a, the fold increases in caspases 3, 6, and
9 were considerably reduced. Correlating with the data in
Table 4, thymocytes were obtained 12hr after CLP. Table 5
describes Annexin V binding to thymocytes from sham rats
(laparotomy without cecal ligation and puncture) and from
rats subjected to CLP following intravenous infusions of
400µg preimmune rabbit IgG or 400µga ﬃnity puriﬁed C5a
neutralizing rabbit IgG. In vitro binding of Annexin V to
thymocytes was quantitated by ﬂow cytometry. As is evident
in Table 5, only 4% of thymocytes from sham rats bound
Annexin V, whereas 12hr after CLP in rats pretreated in vivo
with preimmune IgG, 29% thymocytes bound Annexin V.
In striking contrast, the binding of Annexin V to
thymocytes from CLP rats treated with neutralizing anti-
C5a antibody fell to 7%. Collectively, these data indicate that
thymocyte apoptosis can be linked to C5a, C5aR and early
elevation in C5a binding to thymocyte C5aR following CLP.
It seems likely that events of this type may apply in general to
the lymphoid system as a whole in the setting of sepsis.Critical Care Research and Practice 5
Table 5: Apoptosis of rat thymocytes 12hr after CLP∗.
Condition Annexin V binding (% positive thymocytes)
sham 4%
CLP + preimmune rabbit IgG (400µg)







∗Thymocytes were obtained 12hr after CLP and assessed in ﬂow cytometry for binding of Annexin V.
Adapted from [20].
7. Developing Anti-C5a Antibodiesfor
Use in Humans
7.1. General Aspects. There is abundant literature from var-
ious scientiﬁc groups detailing the important role of C5a
in acute inﬂammatory diseases and especially in sepsis. As
indicated above, this evidence goes back many years, to the
1980s [22, 23]. In the meantime, a much more in-depth
understanding about the molecular and cellular mechanisms
involved in C5a-induced harmful in vivo eﬀects in sepsis
is now available. It is therefore reasonable to ask the
question why no eﬀective compounds targeting C5a or
its receptors have yet been developed by pharmaceutical
companiesthatdisplayagrowinghungerforpotentialblock-
buster drugs by targeting key players that are driving disease
progression in humans. There is no easy answer to this
question, but the following reasons may have contributed.
(1) The complement system has long been perceived as
being dangerous to “play” with. Such reluctance to tamper
with complement stands in striking contrast to the eﬀorts
over the past 50 years to suppress adaptive immunity as
related to allografts in humans, knowing full well that
immunosuppression, if excessive, can lead to catastrophic
outcomes in humans. As a major participant in the innate
immune system, complement has been considered to be
sacrosanct. Many clinicians and scientists have been aware
of the role of complement in its antimicrobial role exerted
through the terminal membrane attack complex [5] and the
important opsonic function of C3b leading to a stimulation
of the immune response, but information did not generally
extend beyond these areas. Due to the complexity of the
complement system and its obvious importance in both
innateimmunityandadaptiveimmunity,thereseemstohave
been an instinctive reluctance to develop drugs that block
components of the complement system. In addition, certain
drugs targeting the upstream complement components such
as C1 inhibitor did not demonstrate convincing therapeutic
potential in humans [24]. (2) C5a is an especially diﬃcult
target for drug development. It can be produced in large
amounts in the plasma within minutes, but yet it is elusive
and diﬃcult to measure because of the various mechanisms
for its removal from the blood stream (binding to receptors
on blood leukocytes, rapid clearance in the kidneys, etc). In
addition, C5a is a small molecule that is cleaved from of its
parent molecule, C5, and it is clear that many antibodies
binding to C5a will also bind to C5. The latter observation
implies a potential for such antibodies to interfere with C5b-
induced formation of the MAC. Loss of C5 function in sepsis
would be a highly undesirable outcome since MAC causes
lysis of Gram-negative bacteria.
7.2. Selecting an Anti-C5a Approach versus an Anti-C5aR
Approach. Given the above-mentioned concerns, one might
speculate whether it might be better and easier to develop
anti-C5aR antibodies. From a technical perspective, this
appears to be true, and there is evidence in experimental
sepsis that anti-C5aR and even also anti-C5L2 antibodies
exert beneﬁcial eﬀects [5]. However, one needs to consider
that there is an abundant amount of these receptors on
almost all cell types. One neutrophil alone is estimated to
display approximately 200,000 C5a binding receptors on its
surface [25]. In addition, we were able to demonstrate that
C5aR is induced in various organs and cell types during the
development of sepsis (CLP) in rodents [3]. C5a binds very
rapidly to these receptors and, in order to achieve a complete
blockade of C5a-induced eﬀects, it would likely be necessary
to block virtually all available receptors. With this in mind,
one might speculate if it would be more eﬃcient to block
C5a directly rather than C5aR. On the other hand, various
researchreportshavedemonstratedhighlysigniﬁcantbeneﬁ-
cialeﬀectsforoutcomeduringexperimentalsepsisinrodents
using either blocking antibodies or small chemical inhibitors
to C5aR. It should be mentioned that Novo Nordisc has
developed the ﬁrst anti-human C5aR antibody for use in
clinical phase I trials, for application in rheumatoid arthritis
(according to the company’s press release). As far as our
understanding currently goes, it remains to be determined
in future clinical trials, using blockade of C5aR or C5a
directly, which target might be more beneﬁcial in the setting
of inﬂammatory diseases, including sepsis.
7.3. Blocking C5—An Approach That Has Made It to the
Market with Great Success but May Be with Associated Risks.
From a technical perspective, blocking C5 with an antibody
is a much easier strategy than a blocking antibody to C5a
that often also reacts with C5. The C5 molecule is present
in large amounts in the serum. However, due to the size of
C5a and C5b, antibodies which bind to C5 and eﬀectively
block formation of C5a would do so primarily by depleting
C5 or preventing cleavage of C5 to C5a and C5b. Such
antibodies would therefore compromise the function of C5b
and the related MAC as well as leading to susceptibility of
treated patients towards bacterial and other microorganism-
driven infections. However, for life-threatening diseases that
are primarily driven by the action of MAC, such antibodies6 Critical Care Research and Practice
represent a valuable therapeutic strategy. The high risk for
developing bacterial infections might be counteracted by
immunization of patients before the use of an antibody that
depletes C5.
It is not surprising that an eﬀective humanized anti-C5
antibody has been successfully developed into a marketed
product (Soliris: Eculizumab by Alexion Pharmaceuticals).
This development has provided great hope for researchers
and biotech and pharmaceutical companies that are trying
to prove that great potential lies in blocking selected targets
within the complement system in the setting of various
diseases. Soliris is currently approved for use in paroxysmal
nocturnal hemoglobinuria (PNH), a disease which is driven
by complement-induced lysis of red blood cells and other
cells within the immune system, due to a genetic defect
leading to a lack of an anchor protein which holds a cell
bound complement inhibitor on the cell surface. Soliris
has displayed excellent lifesaving therapeutic potential in
PNH patients. Recent reports suggest that treatment of such
patients with Soliris appears to result in relatively normal
life expectancy [26]. Because of the antibody amount needed
for an eﬀective C5 blockade (normal serum levels up to
400nM),andduetohigh development costsofSoliris aswell
as PNH being a small market, the average yearly treatment
costs exceed $300,000 (USD) per patient.
Soliris is about to receive marketing authorization for
use in atypical hemolytic uremic syndrome (aHUS) in the
USA within the next few months. aHUS is a disease in which
the role of MAC versus C5a is not understood in detail.
However, Alexion has been also conducting clinical phase II
trials using Soliris in other acute inﬂammatory diseases, such
as antibody-mediated transplant graft rejection following
kidney transplantation, in which it might be speculated
whether C5a is the disease-driving key element rather than
the MAC. If this were true, a C5a speciﬁc blocking antibody
which would not interfere with C5b and MAC formation
would be expected to be a more desirable strategy for
treatment. A high eﬃcacy antibody could be used at lower
concentrations and such antibody application might not
display the associated risks of infection. This would be of
great importance for immune-compromised patients such as
transplant recipients.
Due to the associated risks of Soliris related to blocking
MAC formation, patients receiving this antibody need to
be immunized against meningococcal infections to prevent
from meningococcal-induced sepsis. It is well known that
humans with absence of C5 have susceptibility to neisserial
infections. Itisthereforeimplied thata C5blocking antibody
should not be used in acute inﬂammatory diseases which
are microbial driven, such as sepsis and others. A recent
publication from the Ward laboratories [27] used mice
depleted of C6 by an antibody, which would be expected
to largely prevent MAC formation in the setting of CLP.
Blood CFUs were evaluated 24hr after CLP. Wt mice had
approximately 2×105 CFUs/mL, C3−/− mice had a 4-fold
increase, and C5−/− CLP mice had a 400-fold increase in
blood CFUs. C6 “depleted” CLP mice had CFU levels that
were 15-fold higher than complement-intact mice. The fold
increase in these mice was probably much lower compared
to C5−/− because of incomplete depletion of C6. These data
suggest that the MAC plays an important protective role in
the setting of CLP in mice.
7.4. Technical Aspects and Requirements for Development
of Eﬀective Anti-C5a Antibodies. Obviously, designing an
eﬀective antibody for blocking C5a for use in humans
appears to be rather diﬃcult since no such molecule has yet
been developed for clinical testing in patients (as far as being
currently publically disclosed). From a purely technological
standpoint, generating antibodies can be easily achieved
using various diﬀerent platforms for obtaining standard
molecules following immunization of animals (polyclonal or
monoclonal antibodies). Humanization of mouse antibodies
can be done in the case of monoclonal antibodies or even
fully human monoclonal molecules can be derived from
phage display libraries and also from genetically modiﬁed
animals that generate human molecules. There is great
debate in the literature about the questions of which of these
groups of antibodies may have most favorable biological
features. However, one consensus appears to be that every
molecule is unique and will contain unique properties which
may or may not be typical for its group. In the end, one
question always remains to be answered: how eﬀectively
does the molecule do what it is assumed to do: block C5a
biological eﬀects in vivo?
8. Featuresof Desirable Antibodies
From a researcher’s perspective the following requirements
should be met for a suitable anti-C5a monoclonal antibody
candidate:
(i) high biological blocking eﬃcacy;
(ii) high C5a selectivity—no interference of C5 and C5b;
(iii) fast, robust, and strong binding to C5a;
(iv) no binding to other targets (cell surfaces, receptors,
etc.);
(v) low immunogenicity (low anti-drug antibody forma-
tion);
(vi) desirable half-life in serum;
(vii) desirable biological activity over time.
8.1. High Blocking Eﬃcacy. This requirement is impor-
tant because C5a can be produced in large amounts—
theoretically up to the total amount of serum C5 if every
molecule C5 would be cleaved (400nM). Therefore, strong
biological eﬃcacy of an antibody would guarantee a lower
total amount of antibody to be needed in acute settings such
as sepsis. Since low amounts of C5a (10nM) are capable of
signiﬁcantly boosting immunological responses in vitro, it
would be important to be able to completely suppress C5a-
induced biological eﬀects. Ultimately, high antibody eﬃcacy
could also result in lower costs of a product in the market.
8.2. High C5a Selectivity. As outlined in detail above, this
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and MAC formation would be undisturbed such that
eﬀective microbial removal through complement-induced
lysis would be possible. However, selectivity may be the most
diﬃcult feature to be achieved because of the following fact.
According to crystal structure analysis in a recent work by
Fredslund et al. [28] it becomes clear that binding epitopes
of C5a, which are most important for the interaction with its
receptors (C5aR and C5L2), are facing the outside within the
parent molecule C5 (before cleavage). Biologically eﬀective
blockingantibodiestargetingC5amustbindtosuchepitopes
in order to hinder C5a from interacting with its receptors.
Thus,suchmoleculesarehighlylikelytobindnotonlytoC5a
but also to C5. Therefore, ﬁnding a functional neoepitope on
C5a but not on C5 is the ﬁrst challenge to overcome for the
development of such a therapeutic antibody.
8.3. Rapid Binding. The binding of C5a to its receptors
occurs rapidly, leading to activation of C5a receptors and
in case of C5aR to the internalization of the C5a•C5aR
complex.Therefore,itisexpectedthatausefulanti-C5amAb
should have a binding constant to its target (C5a) lower than
theoneofC5atoitsreceptorsinordertoassurethatantibody
present in serum would be binding newly generated C5a
before the C5a would react with its receptors.
8.4. No Binding to Other Targets/Structures. It has become
increasingly clear that unwanted features of antibodies
could result in serious consequences [29]. Ultimately, an
antibody binding to a circulating protein should ideally
not bind to surfaces, receptors or other proteins that could
interact with cell biological processes and trigger a biological
response (“agonist antibodies”). Therefore, an anti-C5a
antibodyunderdevelopmentmustbescreenedforunwanted
cytotoxic/immunotoxic and other eﬀects.
8.5.LowImmunogenicity. Formationofanti-drugantibodies
isawell-knownproblem,evenifnotpredictablebasedonthe
structure of the monoclonal antibody, the outcome of which
could limit biological eﬃcacy and availability of monoclonal
antibodies. This problem would be most relevant when
a drug is intended for long term use, requiring multiple
injections. Since long term administration of antibody is not
likely in the case of sepsis, it needs to be kept in mind that
internationalguidelinesrequirethedevelopmentofvalidated
tests demonstrating the extent of anti-drug antibody for-
mation in humans. Formation of such antibodies must be
further evaluated with regard to impacts on the biological
eﬃcacy of the antibody.
8.6. Desirable Half-Life and Biological Activity in Serum.
Complement activation should be ongoing not only during
the initial phase of sepsis development but probably also
during the course of sepsis. It is important to generate
antibodies that will be available and biologically active
during a time span of at least several days. This feature
will guarantee protection from C5a induced harmful eﬀects
over a time exceeding the initial hours of sepsis develop-
ment. Presently, various possibilities exist to alter antibody
clearance through induced changes in the antibody on a
molecular level. Diﬀerent IgG structures (IgG1, IgG2, IgG4,
etc.) are commonly used to preselect certain desired half-life
features and also some associated immunological reactions
(e.g., Fc-mediated complement activation, etc.).
8.7. Safety and Therapeutic Rational for Use of Anti-C5a
Antibodies in Patients with Sepsis. Since the Soliris product,
anti-C5 antibody, which also prohibits generation of C5a
because of C5 depletion or blockade, has been approved
and because the available data in the development program
indicate a very good safety and tolerability proﬁle, one may
assume that an anti-C5a antibody, being more speciﬁc and
leaving C5b and MAC formation untouched, should be
safe and well tolerated in humans. One unsolved question
is whether a complete blockade of baseline C5a levels in
humans would impact physiologically relevant processes and
therefore be potentially harmful. On the other hand, the
duration of antibody administration would likely be limited
to days rather than weeks.
Given the available data in the literature as reviewed,
C5a activation occurs early in experimental sepsis and
signiﬁcantly contributes to subsequent organ dysfunction
and organ failure. C5a thereby appears to be a key player
responsible for boosting various immunological inﬂamma-
toryprocessesearlyinsepsis.Thismakessensefromabiolog-
ical point of view. In the era before antibiotics, proliferating
bacteria in human blood would usually lead to extreme risk
of death. Weapons would have to be in place, activating
within minutes of infection and amplifying and boosting
inﬂammatory responses with one goal: to get rid of bacterial
presencebeforeexponentialampliﬁcationoftheorganism(s)
occurs. Such would have to occur prior to signiﬁcant organ
damage. With this rationale in mind, it appears reasonable to
attempt a rather early or even prophylactic approach for tar-
getingC5aasaharmfulkeyplayerinsepsis,whilekeepingup
high standards of supportive care and an early focus on erad-
ication of bacteria with antimicrobial therapy. Trial designs
will have to allow for administration of a drug targeting C5a.
However, until today, little is known about the role of C5a
in later phases of sepsis and its postulated contribution to
immune paralysis in later phases of sepsis in humans. Trials
answering this question will be needed but may be less likely
to result in substantial clinical impact for the septic patient
who is displaying organ dysfunction or failure.
9. The Future
In view of the lack of highly eﬀective drugs for the treatment
of human sepsis, the expanding evidence suggests the possi-
ble roles of the complement activation product, C5a, and its
receptors (C5aR and C5L2) as targets in the highly damaging
and lethal consequences of sepsis. Collectively, the data
suggest that, in patients with sepsis, use of an antibody that
neutralizes C5a but does not cause C5 blockade/depletion
may hold clinical promise. The characteristics of the ideal
antibody to C5a are continuing to be determined. Clinical
trials featuring the use of such an antibody in human sepsis
hold considerable promise.8 Critical Care Research and Practice
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